Bone Fracture - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 75
Inquire Before Buying

Bone Fracture - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H2 2018, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Bone Fracture - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bone Fracture - Overview
Bone Fracture - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Fracture - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Fracture - Companies Involved in Therapeutics Development
Biopharm GmbH
Bone Therapeutics SA
Entera Bio Ltd
ethris GmbH
Hemostemix Inc
Kolon TissueGene Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Viking Therapeutics Inc
Bone Fracture - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCSVT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-008399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Fracture - Dormant Projects
Bone Fracture - Discontinued Products
Bone Fracture - Product Development Milestones
Featured News & Press Releases
Jul 17, 2018: Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study
Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells' Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bone Fracture, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Bone Fracture - Pipeline by Biopharm GmbH, H2 2018
Bone Fracture - Pipeline by Bone Therapeutics SA, H2 2018
Bone Fracture - Pipeline by Entera Bio Ltd, H2 2018
Bone Fracture - Pipeline by ethris GmbH, H2 2018
Bone Fracture - Pipeline by Hemostemix Inc, H2 2018
Bone Fracture - Pipeline by Kolon TissueGene Inc, H2 2018
Bone Fracture - Pipeline by Kuros Biosciences AG, H2 2018
Bone Fracture - Pipeline by Laboratorios SALVAT SA, H2 2018
Bone Fracture - Pipeline by Novartis AG, H2 2018
Bone Fracture - Pipeline by Viking Therapeutics Inc, H2 2018
Bone Fracture - Dormant Projects, H2 2018
Bone Fracture - Dormant Projects, H2 2018 (Contd..1), H2 2018
Bone Fracture - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Bone Fracture, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Substance Abuse Treatment Market Data Survey Report 2025
    Published: 09-Nov-2018        Price: US 1500 Onwards        Pages: 71
    Summary The global Substance Abuse Treatment market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing sites, ca......
  • Global Thyroid Gland Disorders Treatment Market Research Report 2018
    Published: 07-Nov-2018        Price: US 2900 Onwards        Pages: 110
    This report studies the global Thyroid Gland Disorders Treatment market status and forecast, categorizes the global Thyroid Gland Disorders Treatment market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - GlaxoSmithKline - Pfizer, Inc - Novartis I......
  • Global Endometriosis Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 05-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Therapies used to treat endometriosis include: Hormonal contraceptives. Birth control pills, patches and vaginal rings help control the hormones responsible for the buildup of endometrialtissue each month Scope of the Report: The worldwide market for Endometriosis Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. ......
  • Global Venous Leg Ulcers Treatment Market Data Survey Report 2025
    Published: 26-Oct-2018        Price: US 1500 Onwards        Pages: 80
    Summary The global Venous Leg Ulcers Treatment market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing sites, c......
  • Global and United States Hormone Replacement Therapy Market Research by Company, Type & Application 2013-2025
    Published: 25-Oct-2018        Price: US 2000 Onwards        Pages: 111
    Summary Market Segment as follows: By Type - Estrogen replacement therapy - Growth hormone replacement therapy By Application - Oral - Parenteral - Transdermal By Company - F. Hoffmann-La Roche - Merck Serono - Novartis - Novo Nordisk - Pfizer - Abbott Laboratories - ANI Pharmaceuticals - Bayer - Eli Lilly - Hisamitsu Pharmaceutical ......
  • Global Acute Ischemic Stroke Therapeutics Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 135
    AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternat......
  • Global and United States Peptide Therapeutics Market Research by Company, Type & Application 2013-2025
    Published: 22-Oct-2018        Price: US 2000 Onwards        Pages: 111
    Summary Market Segment as follows: By Type - Injection - Oral - Other By Application - Cancer - Metabolic Disorders - Central Nervous System - Others By Company - Sanofi - Teva - Novo Nordisk - Takeda - Eli Lilly - AstraZeneca - Novartis - Shire - AbbVie - Ipsen - Allergan - Ferring - Merck - The Me......
  • Global and United States Clostridium Difficile Treatment Market Research by Company, Type & Application 2013-2025
    Published: 20-Oct-2018        Price: US 2000 Onwards        Pages: 111
    Summary Market Segment as follows: By Type - Narrow Spectrum Antibiotics - Broad Spectrum Antibiotics By Application - Hospitals - Clinics - Others By Company - Actelion Pharmaceuticals - Merck - Pfizer - Summit Therapeutics - Astellas Pharma - CRESTOVO - Da Volterra - Immuron - MGB Biopharma - Novartis - Otsuka Pharmaceutical ......
  • Global Biologic Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 136
    Biologic therapeutics drugs are genetically engineered proteins derived from human genetic material. They contain sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. In addition, biologics drugs are derived from natural sources such as animals, humans, and microorganisms that are further utilized to make therapeutic products such as vaccines, blood components, and recombinant therapeutic proteins. Scope......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs